ArticleClinical and translational medicine2026
Non-canonical function of transferrin receptor-1 promotes breast cancer metastasis by activating HCK‒STAT3‒MMP9 signalling.
Article in Clinical and translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundTransferrin receptor 1 (TfR-1), a key mediator of cellular iron uptake, is significantly upregulated across a broad spectrum of malignancies, and its overexpression highly correlated with poor clinical outcomes, such as in breast cancer. However, its precise role in breast cancer progression remains unclear.
methodsWe integrated clinical breast cancer tissue specimens and public transcriptomic datasets to analyse the clinical correlation between TfR-1 expression and tumour metastasis. A series of in vitro cell functional assays and in vivo xenograft tumour metastasis models were performed to validate the regulatory effect of TfR-1 on breast cancer proliferation and metastasis. Co‑immunoprecipitation, phosphorylation detection and protein stability assays were further applied to dissect the intermolecular regulatory network among TfR-1, Hematopoietic Cell Kinase (HCK) and Ubiquitin Specific Peptidase 32 (USP32).
resultsClinical data analysis revealed that elevated TfR-1 expression was tightly linked to metastatic phenotype in breast cancer. Functional experiments confirmed that upregulated TfR-1 robustly boosted the proliferative and metastatic capacity of breast cancer cells in vitro and in vivo. Mechanistically, TfR-1 dual‑regulates HCK, it directly induces HCK phosphorylation, while simultaneously activating USP32 to block HCK protein degradation and sustain HCK abundance. Activated HCK further triggers STAT3 transcription factor signalling, which drives the upregulation and secretion of matrix metalloproteinase 9 (MMP9). In addition, HCK reciprocally phosphorylates TfR-1 to establish a positive feedback circuit amplifying the prometastatic signalling.
conclusionsThis work identifies a previously uncharacterized prometastatic function of TfR-1 independent of its canonical iron transport activity in breast cancer. We uncover a reciprocal TfR‑1/HCK positive feedback axis that activates the USP32‑HCK‑STAT3‑MMP9 signalling cascade to facilitate breast cancer metastasis, which provides novel candidate therapeutic targets for metastatic breast cancer intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.